AstraZeneca Ultomiris cuts proteinuria by 43.4% in nephropathy trial
AstraZeneca's Ultomiris demonstrated a 43.4% reduction in proteinuria compared to placebo in adults with immunoglobulin A nephropathy at 34 weeks in a phase trial.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
Hubs
Briefings
More story pages
Pfizer's VESPER-1 trial shows nearly 16% weight loss at 32 weeks on weekly BEROBENATIDE
Pfizer announced that its VESPER-1 clinical trial showed nearly 16% weight loss at 32 weeks with a 2.4 mg weekly dose of BEROBENATIDE.
US Ebola Patient Cured After Treatment in Germany, Hospital Says
A US man who caught Ebola in the Democratic Republic of Congo has been cured after treatment in Germany, according to the hospital.
WHO confirms nearly 500 Ebola cases in central Africa outbreak.
WHO confirmed nearly 500 Ebola cases in the central Africa outbreak, with growing concern over its scale.
Pfizer aims to enter obesity drug market with new treatments, targeting industry leadership in growing sector.
Pfizer currently lacks any obesity drugs on the market but plans to change that and establish itself as an industry leader.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.